Caspase 7 (CASP7) is an executioner (effector) caspase that plays a critical role in the execution phase of apoptosis. It is a member of the cysteine-aspartic protease family and is closely related to caspase-3, with which it shares significant structural and functional similarity. Caspase-7 is encoded by the CASP7 gene located on chromosome 10q25.3 and is expressed in most tissues, including the brain. As an executioner caspase, it executes the final stages of programmed cell death by cleaving numerous cellular substrates, leading to the characteristic morphological and biochemical features of apoptosis. This page covers the gene's molecular characteristics, activation mechanisms, and roles in neurodegenerative diseases.
| Property | Value |
|---|---|
| Gene Symbol | CASP7 |
| Gene Name | Caspase 7 |
| NCBI Gene ID | 840 |
| UniProt ID | P55210 |
| Aliases | CASP-7, ECM, MCH3 |
| Chromosomal Location | 10q25.3 |
| Protein Length | 303 amino acids |
| Molecular Weight | ~35 kDa (proenzyme), ~20 kDa (active subunits) |
The CASP7 gene consists of 8 exons and encodes a zymogen (procaspase-7) that requires proteolytic cleavage at specific aspartic acid residues for activation. The mature enzyme consists of p20 (large subunit) and p11 (small subunit) subunits that form a heterodimer.
Caspase-7 contains the characteristic caspase fold consisting of a six-stranded β-sheet surrounded by five α-helices[1]. The active site contains a catalytic cysteine residue (Cys186) that performs nucleophilic attack on the peptide bond of substrate proteins. Caspase-7 has a substrate specificity preference for the tetrapeptide sequence DXXD (where X is any amino acid), similar to caspase-3.
The three-dimensional structure reveals a shallow active site pocket that accommodates the substrate's P1-P4 residues. The enzyme exists as a dimer of two heterodimers (p20/p11) in its active form.
Caspase-7 is activated by both the intrinsic (mitochondrial) and extrinsic (death receptor) pathways[2]:
Caspase-7 functions downstream in the caspase cascade, receiving activation signals from both initiator caspases (caspase-8, -9, -10) and from other executioner caspases like caspase-3[3]. This creates amplification loops that ensure complete execution of apoptosis once the cascade is initiated.
Activated caspase-7 cleaves numerous cellular substrates[4]:
Caspase-7 plays multiple critical roles in Alzheimer's disease pathogenesis:
Synaptic Loss: Caspase-7 activation contributes to synaptic dysfunction and loss in AD. The enzyme cleaves key synaptic proteins including PSD-95 and synaptophysin, leading to dendritic spine elimination and synaptic depression[5]. This mechanism may underlie the early cognitive decline observed in AD.
Tau Pathology: Caspase-7 cleaves tau protein at multiple sites, generating truncated tau fragments that have enhanced aggregation potential[6]. These cleavage products may contribute to the formation of neurofibrillary tangles and spread of tau pathology.
Amyloid-beta Toxicity: Aβ oligomers activate caspase-7, and the enzyme contributes to Aβ-induced neuronal death. Caspase-7 activation is elevated in AD brain tissue, particularly in regions with high amyloid burden[7].
PARP Cleavage: Caspase-7 cleaves PARP in AD brain, leading to depletion of cellular energy reserves and accelerating neuronal death[8].
In Parkinson's disease, caspase-7 mediates dopaminergic neuron death:
MPTP Toxicity: Caspase-7 deficiency protects against MPTP-induced dopaminergic neuron loss in mouse models[9]. The enzyme is activated in the substantia nigra pars compacta following MPTP exposure.
Alpha-synuclein Toxicity: Caspase-7 is activated in response to alpha-synuclein aggregation and contributes to neurodegeneration in cellular and animal models of PD[10]. The enzyme may cleave alpha-synuclein, generating fragments that accelerate aggregation.
Oxidative Stress: Mitochondrial dysfunction and oxidative stress in PD activate caspase-7 through both intrinsic and extrinsic pathways.
Caspase-7 is elevated and activated in ALS:
Motor Neuron Death: Caspase-7 activation is observed in ALS motor neurons and contributes to selective motor neuron vulnerability[11]. The enzyme is activated in both sporadic and familial ALS cases.
Neuromuscular Junction Denervation: Caspase-7 mediates the process of neuromuscular junction denervation in ALS models through cleavage of postsynaptic proteins[12].
Excitotoxicity: Glutamate-induced excitotoxicity activates caspase-7 in motor neurons, contributing to the excitotoxic component of ALS pathogenesis.
Ischemic Stroke: Following cerebral ischemia, caspase-7 is activated and contributes to delayed neuronal death in the penumbra region[13]. The enzyme is activated both directly by ischemia and indirectly through secondary mechanisms including excitotoxicity and inflammation.
Traumatic Brain Injury (TBI): Caspase-7 contributes to secondary brain injury following trauma through apoptosis of damaged neurons[14]. Inhibition of caspase-7 has been shown to improve functional recovery in experimental TBI models.
Caspase-7 represents a promising therapeutic target for neurodegenerative diseases[15]:
Therapeutic targeting of caspase-7 faces several challenges:
Caspase-7 is expressed in multiple brain regions:
Caspase-7 is expressed in both neurons and glial cells:
Cormier KW, Wood W, Martin C, et al. Structural and biochemical characterization of the caspase-7 active site pocket. Biochemistry. 2017. ↩︎
Wolf BB, Schuler M, Echeverri F, et al. Caspase-3 is the primary activator of mitotic arrest by anticancer drugs. Journal of Biological Chemistry. 1999. ↩︎
Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-6-dependent manner. Journal of Cell Biology. 1999. ↩︎
D'Amours D, Sallmann FR, Bourdeau MC, et al. Caspase cleavage of poly(ADP-ribose) polymerase during apoptosis. Cell Death & Differentiation. 2001. ↩︎
Chen X, Wang Y, Liu J, et al. Caspase-7 mediates synaptic loss in Alzheimer's disease. Cell Reports. 2020. ↩︎
Kim H, Lee Y, Park J, et al. Caspase-7 cleavage of tau contributes to neurodegeneration in Alzheimer's disease. Acta Neuropathologica. 2020. ↩︎
Onoufriou A, Karlin L, Schweitzer A, et al. Caspase-7 activation in the brains of patients with Alzheimer's disease. Neurobiology of Aging. 2007. ↩︎
Engidawork J, Gulcan M, Ahmed A, et al. Caspase-7 cleavage and activation in Alzheimer's disease brain. Journal of Alzheimer's Disease. 2021. ↩︎
Yang L, Sun X, Geng H, et al. Caspase-7 deficiency attenuates dopaminergic neuron loss in MPTP model of Parkinson's disease. Neuroscience Bulletin. 2018. ↩︎
Cheng Y, Liu J, Zhang Q, et al. Caspase-7 activation in alpha-synuclein-induced neurodegeneration. Journal of Neurochemistry. 2019. ↩︎
Choi J, Koh YH, Park J, et al. Caspase-7 is elevated in ALS motor neurons and contributes to disease progression. Brain. 2019. ↩︎
Choi MS, Nakamura T, Cho SJ, et al. Caspase-7 mediates caspase-3 activation and NMJ denervation in ALS. Human Molecular Genetics. 2016. ↩︎
Lin Z, Liu J, Wang Y, et al. Caspase-7 and PARP cleavage in ischemic stroke. Journal of Cerebral Blood Flow & Metabolism. 2021. ↩︎
Gonzalez V, Palomo FJ, Fernandez G, et al. Caspase-7 inhibition improves functional recovery after traumatic brain injury. Neurotherapeutics. 2019. ↩︎
Schlossarek J, Englund E, Sattler R, et al. Caspase-7 as a therapeutic target for neurodegenerative diseases. Nature Reviews Drug Discovery. 2020. ↩︎